ATB Tx
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Oncology
atbtherapeutics is a Belgium‑based, preclinical‑stage biotechnology company developing next‑generation targeted therapies. The company engineers novel biologics that integrate differentiated cell‑killing mechanisms directly within targeted antibodies, including proprietary enzymatic functionalities. These heterobifunctional “Atbody” constructs combine multiple targeting and killing domains in a single molecule, offering greater precision, potency, and safety than traditional antibody–drug conjugates.
The company’s pipeline includes a lead Atbody program for non‑Hodgkin lymphoma (NHL), with a Clinical Trial Application (CTA) planned for the end of 2027. A second program in inflammation and immunology (I&I) is advancing toward clinical candidate selection by the end of 2026. In November 2024, atbtherapeutics secured a €54 million Series A round to accelerate development of its platform and progress its first assets toward the clinic.
Company HQ City:
Aye
Company HQ State:
Luxembourg
Company HQ Country:
Belgium
Year Founded:
2018
Lead Product in Development:
ATB-101 : Non Hodgkin Lymphoma
CEO
Bertrand Magy
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
1
When you expect your next catalyst update?
December 2026
What is your next catalyst (value inflection) update?
The company’s pipeline includes a lead Atbody program for non‑Hodgkin lymphoma (NHL), with a Clinical Trial Application (CTA) planned for the end of 2027. A second program in inflammation and immunology (I&I) is advancing toward clinical candidate selection by the end of 2026.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}